Comparative Pharmacology
Head-to-head clinical analysis: LENALIDOMIDE versus POMALYST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENALIDOMIDE versus POMALYST.
LENALIDOMIDE vs POMALYST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
None Documented
Clinical Note
moderateLenalidomide + Digitoxin
"Lenalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLenalidomide + Deslanoside
"Lenalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLenalidomide + Acetyldigitoxin
"Lenalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateLenalidomide + Ouabain
"Lenalidomide may decrease the cardiotoxic activities of Ouabain."
None Documented
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent